MVIS US Listed Pharmaceutical 25 Index
The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that derive at least 50% of their revenues from pharmaceuticals. The pure-play index contains only companies which are engaged primarily engaged in research (incl. research contractors) and development as well as production, marketing and sales of pharmaceuticals. Pharmacies are excluded. The MVIS US Listed Pharmaceutical 25 Index (MVPPH) has been licensed to underlie financial products with currently USD 157.99 million in assets under management.
This page compares selected fundamental data of the MVIS Index to designated peer indices. The data is updated monthly.
|Trailing Price/Earnings (incl. negative)||-74.09 |
|Price/Cash Flow||8.30 |
|Dividend Yield||2.05 |
|Net Debt to Equity||1.03 |